Hansoh Pharma's Obesity Drug Olatorepatide Achieves 19.3% Weight Loss in Phase III Trial

Hansoh Pharma announced results from its Phase III clinical trial for olatorepatide, a dual-acting GLP-1/GIP receptor agonist developed for weight management. The findings were presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan.

The LIGHTEN study involved 604 overweight or obese Chinese adults. At the 48-week mark, participants receiving the 15 mg dose of olatorepatide experienced an average weight loss of 19.3%. The trial data indicated a consistent downward trend in weight loss without reaching a plateau, suggesting potential for further benefits with longer treatment duration.

In addition to weight reduction, olatorepatide demonstrated positive effects on various metabolic parameters. The 15 mg dose resulted in an average waist circumference reduction of 16 cm. The drug also showed improvements in blood pressure, lipid profiles, and insulin resistance.

The safety profile of olatorepatide was reported as favorable, with a lower incidence of gastrointestinal adverse events compared to similar medications. Nausea occurred in 7.8% of participants and vomiting in 4.9%. The company stated that no participants discontinued the trial due to treatment-related adverse events.

Olatorepatide represents a new signaling pathway approach for weight management, aiming to balance efficacy with tolerability. Hansoh Pharma believes the drug has the potential to become a significant new treatment option for individuals struggling with obesity.